Almirall, S.A.
BME:ALM Stock Report
Almirall Future Growth
Future criteria checks 4/6 Almirall is forecast to grow earnings and revenue by 55.3% and 9.7% per annum respectively. EPS is expected to grow by 54.1% per annum. Return on equity is forecast to be 6.9% in 3 years.
Key information
55.3%
Earnings growth rate
Pharmaceuticals earnings growth 25.4% Revenue growth rate 9.7% Future return on equity 6.9% Analyst coverage Good
Last updated 12 Nov 2024
Recent future growth updates
Almirall, S.A. Reiterates Earnings Guidance for Full Year 2024 Nov 11
Almirall, S.A. Reiterates Financial Guidance for Full Year 2024 Jul 22 Almirall, S.A. Provides Earnings Guidance for Full Year 2024
Almirall, S.A. Provides Earnings Guidance for the Year 2024 Feb 20
Consensus EPS estimates increase by 15% Jan 30
Consensus EPS estimates increase by 29% Nov 19
Show all updates
Almirall, S.A. Reiterates Earnings Guidance for Full Year 2024 Nov 11
Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet Nov 06
Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM) Sep 07
Second quarter 2024 earnings released Jul 24
Almirall, S.A. Reiterates Financial Guidance for Full Year 2024 Jul 22
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price Jul 12
Insufficient new directors Jul 01
Almirall’s Ilumetri® (tildrakizumab) Restores and Maintains Wellbeing of Patients With Moderate-to-severe Plaque Psoriasis to the Levels of the General Population for up to 1 Year Jun 29
Dividend of €0.15 announced May 15 Almirall, S.A. Provides Earnings Guidance for Full Year 2024
Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues Apr 24
Almirall, S.A., Annual General Meeting, May 10, 2024 Apr 09
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well Mar 20
Full year 2023 earnings: EPS misses analyst expectations Feb 22
Almirall, S.A. Provides Earnings Guidance for the Year 2024 Feb 20
Consensus EPS estimates increase by 15% Jan 30
Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases Dec 21
Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly Dec 15
Consensus EPS estimates increase by 29% Nov 19
Almirall, S.A. Receives European Commission Approval of EBGLYSS(R) (lebrikizumab) for Moderate to-Severe Atopic Dermatitis Nov 18
Third quarter 2023 earnings released: EPS: €0.008 (vs €0.089 loss in 3Q 2022) Nov 13 Almirall, S.A. to Report Fiscal Year 2023 Results on Feb 19, 2024
Almirall's Ilumetri (Tildrakizumab) Significantly Improves Wellbeing for Patients and Their Relatives in Moderate-To-Severe Plaque Psoriasis Oct 12
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation? Oct 03
Now 21% undervalued Sep 21
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt Aug 24
New minor risk - Shareholder dilution Jul 26
Almirall, S.A. Reiterates Earnings Guidance for the Year 2023 Jul 25
Second quarter 2023 earnings released Jul 24
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation? Jul 05
Almirall Launches Nina, the First Series to Highlight the Major Impact of Psoriasis on Patient’s Wellbeing Jun 20 Almirall, S.A. has completed a Follow-on Equity Offering in the amount of €199.999993 million. Jun 14
New minor risk - Dividend sustainability Jun 13
Is Almirall (BME:ALM) A Risky Investment? May 16
First quarter 2023 earnings released May 10
Consensus EPS estimates fall by 26% May 09
Almirall, S.A. Reiterates Earnings Guidance for the Year 2023 May 08
Estimating The Fair Value Of Almirall, S.A. (BME:ALM) Mar 29
Full year 2022 earnings released: EPS: €0.02 (vs €0.23 loss in FY 2021) Feb 21 Almirall, S.A., Annual General Meeting, May 05, 2023
Now 20% undervalued after recent price drop Feb 13
Price target decreased by 7.2% to €11.93 Feb 01
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt Jan 04
Now 20% undervalued Dec 09
An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued Dec 01 Almirall, S.A. to Report Nine Months, 2023 Results on Nov 16, 2023
Almirall, S.A. Maintains Earnings Guidance for the Full Year of 2022 Nov 10
Almirall, S.A. Announces EMA Acceptance for Filing of Marketing Authorization Application (MAA) for Lebrikizumab in Atopic Dermatitis Oct 28
Almirall, S.A. Announces the 31st EADV Congress the Results from TRIBUTE, an Interventional Phase IV Clinical Study Sep 15
Almirall, S.A. Announces New Detailed Results from Phase 3 Monotherapy Studies in Atopic Dermatitis Sep 09
Second quarter 2022 earnings: EPS misses analyst expectations Jul 26
Almirall (BME:ALM) Seems To Use Debt Quite Sensibly Jul 14
Almirall, S.A.(BME:ALM) dropped from Madrid Ibex 35 Index Jun 22
Happify Health and Almirall, S.A. Go Live with Digital Solution to Support Psoriasis Patients Jun 14
Almirall, S.A. Announces Topline Results from One-Year Analyses of the Efficacy and Safety of Lebrikizumab Jun 07
Almirall, S.A. Announces Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis Apr 12
Now 21% undervalued Mar 31
Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly Mar 23
Now 22% undervalued Mar 03
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price Feb 24
Full year 2021 earnings: EPS and revenues miss analyst expectations Feb 22 Almirall, S.A. Announces Executive Changes
Almirall launches innovative Wynzora® CAL/BDP cream in Europe for the treatment of mild to moderate plaque psoriasis in adults including scalp Feb 19
Almirall Announces Results for Atopic Dermatitis in Third Phase 3 Study Dec 21
Price target decreased to €14.66 Nov 16
Is Almirall (BME:ALM) Using Too Much Debt? Nov 01
Almirall, S.A. Launches Klisyri (Tirbanibulin) for the Treatment of Actinic Keratosis in Europe Sep 29
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price Aug 02
Second quarter 2021 earnings released: €0.40 loss per share (vs €0.036 loss in 2Q 2020) Jul 27
Almirall, S.A. Receives European Commission Approval of Klisyri® (Tirbanibulin) Jul 20
Almirall and MC2 Therapeutics Announce Completion of Decentralized Procedure in Europe for the Topical Treatment of Mild to Moderate Psoriasis Vulgaris in Adults Jul 07
Is Almirall (BME:ALM) Using Too Much Debt? Jul 06
Almirall Receives Positive CHMP Opinion for Klisyri®? (Tirbanibulin), an Innovative Topical Treatment for Actinic Keratosis May 22
First quarter 2021 earnings released: EPS €0.17 (vs €0.28 in 1Q 2020) May 14
Consensus forecasts updated May 11
Here's Why Almirall (BME:ALM) Has A Meaningful Debt Burden Mar 23
New 90-day high: €12.19 Mar 15
How Does Almirall, S.A. (BME:ALM) Fare As A Dividend Stock? Mar 05
Revenue behind estimates Feb 25
Full year 2020 earnings released: EPS €0.42 (vs €0.61 in FY 2019) Feb 25
Analysts lower EPS estimates to €0.46 Feb 23
Almirall U.S. Launches Klisyri® (tirbanibulin), a New, Innovative Topical Treatment for Actinic Keratosis Feb 19
Almirall and MC2 Therapeutics Enters a License, Collaboration and Commercialization Agreement for European Rights to Wynzora® Cream for treatment of Plaque Psoriasis Feb 18
Almirall, S.A. (BME:ALM) Shares Could Be 41% Below Their Intrinsic Value Estimate Feb 15
Analysts lower EPS estimates to €0.43 Feb 12
Earnings and Revenue Growth Forecasts BME:ALM - Analysts future estimates and past financials data (EUR Millions) Date Revenue Earnings Free Cash Flow Cash from Op Avg. No. Analysts 12/31/2026 1,205 94 148 236 9 12/31/2025 1,086 57 117 195 9 12/31/2024 975 11 102 148 9 6/30/2024 932 -35 -115 103 N/A 3/31/2024 915 -39 -48 116 N/A 12/31/2023 899 -38 -66 93 N/A 9/30/2023 907 7 -23 101 N/A 6/30/2023 898 -11 23 156 N/A 3/31/2023 882 -8 37 154 N/A 12/31/2022 879 4 39 155 N/A 9/30/2022 864 9 105 177 N/A 6/30/2022 856 29 98 180 N/A 3/31/2022 843 -50 82 159 N/A 12/31/2021 837 -41 163 234 N/A 9/30/2021 814 -22 204 288 N/A 6/30/2021 809 -11 145 196 N/A 3/31/2021 790 55 122 198 N/A 12/31/2020 814 74 36 113 N/A 9/30/2020 849 63 72 212 N/A 6/30/2020 872 86 49 194 N/A 3/31/2020 926 121 158 296 N/A 12/31/2019 911 106 141 276 N/A 9/30/2019 858 85 -410 190 N/A 6/30/2019 884 88 -368 181 N/A 3/31/2019 789 80 -463 138 N/A 12/31/2018 811 78 -456 143 N/A 9/30/2018 714 -111 105 170 N/A 6/30/2018 730 -179 10 133 N/A 3/31/2018 687 -293 N/A 82 N/A 12/31/2017 677 -304 N/A 6 N/A 9/30/2017 735 -128 N/A -89 N/A 6/30/2017 755 -78 N/A -13 N/A 3/31/2017 821 73 N/A 12 N/A 12/31/2016 822 75 N/A 105 N/A 9/30/2016 778 162 N/A 151 N/A 6/30/2016 743 154 N/A 122 N/A 3/31/2016 721 111 N/A 114 N/A 12/31/2015 738 132 N/A 171 N/A 9/30/2015 783 479 N/A 761 N/A 6/30/2015 802 488 N/A 748 N/A 3/31/2015 842 481 N/A 768 N/A 12/31/2014 828 448 N/A 647 N/A 9/30/2014 868 -13 N/A 56 N/A 6/30/2014 849 -32 N/A 52 N/A 3/31/2014 845 -33 N/A 62 N/A 12/31/2013 825 -34 N/A 67 N/A
Show more
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.8%).
Earnings vs Market: ALM is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ALM is expected to become profitable in the next 3 years.
Revenue vs Market: ALM's revenue (9.7% per year) is forecast to grow faster than the Spanish market (4.9% per year).
High Growth Revenue: ALM's revenue (9.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALM's Return on Equity is forecast to be low in 3 years time (6.9%).
Discover growth companies Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}